Networks

NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search by Keyword field to narrow your search.

Showing results filtered by:

The Consortium of Food Allergy Research (CoFAR) was established in fiscal year (FY) 2005 to support clinical research on food allergy. It was renewed in FY 2010 to continue several promising clinical studies from the original consortium and expanded to include research on the genetic causes underlying food allergy and the mechanisms of food allergy-associated eosinophilic esophagitis.

The long-term goal of the Cooperative Centers on Human Immunology (CCHI) program is the translation of immunology research into clinical applications in humans in the area of infectious disease.

The purpose of the Creative and Novel Ideas in Research (CNIHR) Program is to create a mechanism via the established Centers for AIDS Research (CFARs) to fund developmental projects to bring insight and new ideas from early-stage investigators, some of whom will have expertise in other disciplines, to the HIV/AIDS field of study.

The Division of AIDS (DAIDS) maintains contracts that can potentially provide limited pre-clinical services including manufacturing, analytical chemistry, preclinical pharmacology and toxicology resources to investigators who are working on the development of therapeutics targeting HIV/AIDS and AIDS-related opportunistic infections, including TB.

European and Developing Countries Clinical Trials Partnership (EDCTP)  funds research for prevention and treatment of HIV/AIDS, tuberculosis, malaria, and neglected infectious diseases in sub-Saharan Africa.

The Functional Genomics Program for understanding the functions of uncharacterized genes in infectious disease pathogens aims to generate experimental data to determine the biochemical function(s) of hypothetical genes, unknown open reading frames, and noncoding RNAs.

The NIAID Genomic Centers for Infectious Diseases (GCID) provide insights into the biology of microbes, their role in pathogenesis, and their interactions with the host, including the microbiome, by supporting a diverse set of genomic capabilities, such as next-generation sequencing and related genomic technologies.

NIAID supports and complies with the data sharing policies, including the NIH Genomic Data Sharing (GDS) Policy

An effective and widely available vaccine will be central to any global strategy to slow and end the HIV pandemic.

The mission of the NIAID Intramural Collaborative Program in Global Neglected Infectious Diseases (GNID) is to seek fundamental understanding of neglected infectious diseases and to promote scientific interactions among NIAID investigators engaged in research on neglected tropical diseases (NTDs) and related infections, listed on Neglected Infectious Disease-As

The HIV Prevention Trials Network develops and tests the safety and efficacy of primarily non-vaccine interventions designed to prevent the transmission of HIV.

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.

The NIAID HIV/AIDS Clinical Trials Networks have been designed to address NIAID’s five HIV/AIDS scientific priorities.

The Networks inlcude:

This purpose of this program is to understand how the human leukocyte antigen (HLA) gene region and killer immunoglobulin-like receptor gene family are associated with immune-mediated diseases.

The Human Immunology Project Consortium (HIPC) is a network of researchers established to create a public resource that characterizes the diverse states of the human immune system. HIPC investigators use modern analytic tools to profile the immune system before and after infection, vaccination, or treatment with an adjuvant.

Co-sponsored by NIAID and the Juvenile Diabetes Research Foundation International, the ITN is an international consortium of basic scientists and clinical investigators that performs clinical research to evaluate the safety and efficacy of methods that can induce the immune system to tolerate certain antigens for the treatment of immune-mediated disorders.

The Immunity in Neonates and Infants Program supports research of the developing immune system during the first year of life. This program encourages the use of innovative approaches using human infant tissues and cells, or relevant animal models, to define pathways and mechanisms that contribute to the immune status of the neonate and infant.

The Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP) aims to develop preclinical porcine to nonhuman primate models of islet, kidney, heart, lung, or liver xenotransplantation.

The primary clinical goals of this multi-center clinical trial on HIV+ kidney transplant recipients are to evaluate the impact of CCR5 blockade (maraviroc, MVC) on renal function at week 52 post-transplant; as well as evaluate the overall safety and tolerability of CCR5 blockade in the HIV+ kidney transplant recipient.

The INA-RESPOND is a collaboration between NIAID, the National Institute of Health Research and Development, Ministry of Health of the Republic of Indonesia, and ten major university and clinical centers in Indonesia.

Pages